mTOR and cancer therapy (Q28268516)

A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets.

Europe PubMed Central

title

mTOR and cancer therapy (English)

0 references

author name string

J B Easton

series ordinal

1

0 references

P J Houghton

series ordinal

2

0 references

language of work or name

English

0 references

publication date

16 October 2006

0 references

published in

Oncogene

0 references

volume

25

0 references

issue

48

0 references

page(s)

6436-46

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Clinical development of mammalian target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Increased risk of cancer in the Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Suppression of PI3K/mTOR pathway rescues LLC cells from cell death induced by hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Tuberous sclerosis: from tubers to mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Development by self-digestion: molecular mechanisms and biological functions of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

PIK3CA mutations in breast cancer are associated with poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Induction of autophagy and inhibition of tumorigenesis by beclin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Hypoxia-induced energy stress regulates mRNA translation and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Upregulated expression of the genes encoding translation initiation factors eIF-4E and eIF-2alpha in transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Myc: a weapon of mass destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

The LKB1 tumor suppressor negatively regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

PIK3CA is implicated as an oncogene in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

c-Myc protein synthesis is initiated from the internal ribosome entry segment during apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Elongation factor-2 kinase regulates autophagy in human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

7 January 2021

Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

7 January 2021

4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

7 January 2021

Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

7 January 2021

Expression of eukaryotic translation initiation factors 4E and 2alpha correlates with the progression of thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209886

7 January 2021